Which Key Attributes Will Drive Physician Prescribing and Formulary Inclusion of Current and Emerging PAH Therapies?
Pulmonary arterial hypertension (PAH) is a severe, progressive, debilitating disease marked by considerable morbidity and mortality. Existing PAH drugs increase the expected life span of PAH patients, but clinicians continue to seek novel but safe therapies that can further increase life expectancy, exercise capacity, and time to clinical worsening. There is also an increasing focus on “harder” end points in clinical trials of potential PAH therapies. Following the launch of several agents for PAH in the last few years, the market is becoming increasingly competitive, a status that is expected to continue with the anticipated approval and launch of selexipag in late 2015 and the growing trend toward the use of combination therapy earlier in the treatment algorithm.